SynAct Pharma AB (“SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system, today announces its nomination committee proposes Jeppe Ragnar Andersen, CEO of Sanos Group A/S, a global multi-niche CRO with full service clinical capabilities, to the company’s board of directors. SynAct’s Board of Directors has also appointed Jeppe Ragnar Andersen as a non-voting member of the Board, effective immediately.
“Jeppe has a solid understanding of the life science market and SynAct’s potential for future growth,” said Anders Kronborg, SynAct’s Chairman of the Board. “SynAct is at a key inflection point in its growth plans and having Jeppe’s experience in management of clinical trials will help ensure we are ready to accelerate.”
“I am incredibly pleased Jeppe has accepted the nomination to SynAct’s board. His experience and network are tremendous assets. I am grateful for the expertise he can immediately bring to the company as he is also managing the CRO where we currently do our most important clinical study,” said Jeppe Øvlesen, CEO of SynAct.
“SynAct has done a great job planning and starting its Phase 2b ADVANCE study, and we are all eager to see the company accelerate its plans to help resomelagon reach its full potential,” said Jeppe Ragnar Andersen. I look forward to working with the team to help the company reach is potential.”
Jeppe Ragnar Andersen has extensive experience in the field of managing clinical studies. He is currently CEO of Sanos Group A/S, the parent company of NBCD A/S, which is the CRO leading SynAct’s ongoing Phase 2b ADVANCE study with resomelagon (AP1189) in newly diagnosed severe rheumatoid arthritis (RA). He is also member of the Board of Ousia Pharma ApS and Arctic Therapeutics. He has a Master of Science in Pharmacy from Copenhagen Universtiy and a Master of Business Administration from Quantic School of Business and Technology in the US.
The nomination committee has begun its work in preparation for the 2025 Annual General Meeting, and additional proposals will be presented in due time prior to the meeting.